![Laura Stoppel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Laura Stoppel
Director/Board Member at
ARTIVA BIOTHERAPEUTICS, INC.
Net worth: 33 280 $ as of 31/05/2026
Profile
Laura Stoppel currently works at Acumen Pharmaceuticals, Inc., as Independent Director from 2020, Nimbus Therapeutics LLC, as Director from 2020, CellCentric Ltd., as Director from 2024, Verdiva Bio, Inc., as Director from 2024, Artiva Biotherapeutics, Inc., as Independent Director from 2020, Indapta Therapeutics, Inc., as Director from 2022, International Rett Syndrome Foundation, as Director from 2023, RA Capital Management LP, as Partner from 2024, and RA Capital Management LP (Private Equity), as Principal from 2020.
Dr. Stoppel received her undergraduate degree in 2008 from Harvard University and doctorate degree in 2016 from Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 03/06/2026 | 12,800 ( 0.02% ) | 33 280 $ | 31/05/2026 |
Laura Stoppel active positions
| Companies | Position | Start |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Director/Board Member | 01/06/2020 |
| ACUMEN PHARMACEUTICALS, INC. | Director/Board Member | 01/11/2020 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Private Equity Investor | 01/12/2020 |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical stage biotech company that develops molecule medicines for diseases like cancer, immune disorders and metabolic conditions | Director/Board Member | 01/10/2020 |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Director/Board Member | 01/01/2022 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Analyst-Equity | 01/10/2016 |
International Rett Syndrome Foundation | Director/Board Member | 01/07/2023 |
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule inhibitors for cancer | Director/Board Member | 01/07/2024 |
Training of Laura Stoppel
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
97
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Acumen Pharmaceuticals, Inc.
 Acumen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops medicines and diagnostics for Alzheimer's disease | Health Technology |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Finance |
Nimbus Therapeutics LLC
Nimbus Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical stage biotech company that develops molecule medicines for diseases like cancer, immune disorders and metabolic conditions | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule inhibitors for cancer | Health Technology |
International Rett Syndrome Foundation | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Health Technology |
- Stock Market
- Insiders
- Laura Stoppel
